Article

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasis

2024-02-22

Abstract excerpt

<h4>ABSTRACT</h4> Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastuzumab +/-HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suita...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1643f82c-64b7-5dea-9a1e-6da0524582b6
DOI: 10.1101/2024.02.19.581073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overcoming brain-derived therapeutic resistance in HER2+ breast cancer brain metastasisDOI 10.1101/2024.02.19.581073Read

Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasisSemantic proximity Read

Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.Semantic proximity Read

Insights into the Steps of Breast Cancer–Brain Metastases Development: Tumor Cell Interactions with the Blood–Brain BarrierSemantic proximity Read

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Semantic proximity Read

Metastatic profiling of HER2-positive breast cancer cell lines in xenograft modelsSemantic proximity Read

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapiesSemantic proximity Read

Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.Semantic proximity Read

EGFR as a potent CAR T target in Triple Negative Breast Cancer Brain MetastasesSemantic proximity Read

c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAILSemantic proximity Read

HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.Semantic proximity Read

Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain MetastasisSemantic proximity Read

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read